# A First-in-Human Study of EOS301984 as Monotherapy or Combination Therapy in Adult Participants With Advanced Solid Tumors

> **NCT06547957** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **iTeos Therapeutics** · enrollment: 55 (actual)

## Conditions studied

- Advanced Solid Tumors

## Interventions

- **DRUG:** EOS301984
- **DRUG:** Anti-PD-1 monoclonal antibody

## Key facts

- **NCT ID:** NCT06547957
- **Lead sponsor:** iTeos Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-07-07
- **Primary completion:** 2025-12
- **Final completion:** 2025-12
- **Target enrollment:** 55 (ACTUAL)
- **Last updated:** 2025-08-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06547957

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06547957, "A First-in-Human Study of EOS301984 as Monotherapy or Combination Therapy in Adult Participants With Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT06547957. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*